Cat. No. 3643
Chemical Name: 2-[3-(4-Chlorophenyl)-2-[(2,4-dichl
Biological ActivityProtease-activated receptor 1 (PAR1) antagonist. Exhibits potent antiplatelet activity in vitro; inhibits thrombin TRAP-6-induced platelet aggregation (IC50 = 2.5 μM) with no effect on coagulation time.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Kato et al (2003) Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur.J.Pharmacol. 473 163. PMID: 12892834.
Kato et al (1999) In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur.J.Pharmacol. 384 197. PMID: 10611442.
If you know of a relevant reference for FR 171113 please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses FR 171113 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: FR 171113, supplier, FR171113, thrombin, protease-activated, receptor, 1, PAR1, antagonist, antagonists, antithrombotic, antiplatelet, Tocris Bioscience, Protease-Activated Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Negative control for ELA-32 (Cat.No.6291).ELA-32 (human)
Potent, high affinity apelin receptor agonist; stimulates angiogenesisParathyroid hormone (1-34) (bovine)
Parathyroid hormone (PTH) receptor agonist.Parathyroid hormone (1-34) (rat)
Parathyroid hormone (PTH) receptor agonistPeptide YY (3-36) human
NPY Y2 receptor agonistELA-14 negative control
Negative control for ELA-14 (Cat.No.6293).ELA-14 (human)
Potent apelin (APJ) receptor agonistRetrobradykinin
Reverse analog of BradykininTASP 0390325
Potent and selective V1B receptor antagonist; orally bioavailable
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.